Trial Profile
A prospective study to evaluate efficacy and safety of low dose fenfluramine in Belgian patients with Dravet syndrome
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jan 2018
Price :
$35
*
At a glance
- Drugs Fenfluramine (Primary)
- Indications Dravet syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Zogenix
- 05 Dec 2017 Results presented at the 71st Annual Meeting of the American Epilepsy Society.
- 06 Dec 2016 Results presented at the 70th Annual Meeting of the American Epilepsy Society
- 05 Dec 2016 Updated results published in the Zogenix Media Release.